161 related articles for article (PubMed ID: 37921598)
21. Overexpression of CCDC69 activates p14
Cui L; Zhou F; Chen C; Wang CC
J Ovarian Res; 2019 Jan; 12(1):4. PubMed ID: 30651135
[TBL] [Abstract][Full Text] [Related]
22. Anlotinib Exerts Inhibitory Effects against Cisplatin-Resistant Ovarian Cancer In Vitro and In Vivo.
Ji Y; Li X; Qi Y; Zhao J; Zhang W; Qu P
Molecules; 2022 Dec; 27(24):. PubMed ID: 36558006
[TBL] [Abstract][Full Text] [Related]
23. Protein tyrosine phosphatase receptor type Z1 inhibits the cisplatin resistance of ovarian cancer by regulating PI3K/AKT/mTOR signal pathway.
Wang P; Hu Y; Qu P; Zhao Y; Liu J; Zhao J; Kong B
Bioengineered; 2022 Jan; 13(1):1931-1941. PubMed ID: 35001804
[TBL] [Abstract][Full Text] [Related]
24. Umbilical Cord Blood-Derived M1 Macrophage Exosomes Loaded with Cisplatin Target Ovarian Cancer
Zhang X; Wang J; Liu N; Wu W; Li H; Lu W; Guo X
Mol Pharm; 2023 Nov; 20(11):5440-5453. PubMed ID: 37819754
[TBL] [Abstract][Full Text] [Related]
25. Knockdown of circ-PIP5K1A overcomes resistance to cisplatin in ovarian cancer by miR-942-5p/NFIB axis.
Sheng H; Wang X
Anticancer Drugs; 2023 Feb; 34(2):214-226. PubMed ID: 36730637
[TBL] [Abstract][Full Text] [Related]
26. HIF-1α-dependent miR-424 induction confers cisplatin resistance on bladder cancer cells through down-regulation of pro-apoptotic UNC5B and SIRT4.
Yu M; Ozaki T; Sun D; Xing H; Wei B; An J; Yang J; Gao Y; Liu S; Kong C; Zhu Y
J Exp Clin Cancer Res; 2020 Jun; 39(1):108. PubMed ID: 32522234
[TBL] [Abstract][Full Text] [Related]
27. miR-18a-5p derived from mesenchymal stem cells-extracellular vesicles inhibits ovarian cancer cell proliferation, migration, invasion, and chemotherapy resistance.
Wang X; Jiang L; Liu Q
J Transl Med; 2022 Jun; 20(1):258. PubMed ID: 35672774
[TBL] [Abstract][Full Text] [Related]
28. L-Tetrahydropalmatine enhances the sensitivity of human ovarian cancer cells to cisplatin via microRNA-93/PTEN/Akt cascade.
Gong J; Xing C; Wang LY; Xie SS; Xiong WD
J BUON; 2019; 24(2):701-708. PubMed ID: 31128026
[TBL] [Abstract][Full Text] [Related]
29. Circ_0007841 knockdown confers cisplatin sensitivity to ovarian cancer cells by down-regulation of NFIB expression in a miR-532-5p-dependent manner.
Gao Y; Huang Y
J Chemother; 2023 Apr; 35(2):117-130. PubMed ID: 35380509
[TBL] [Abstract][Full Text] [Related]
30. Downregulation of LINC01508 contributes to cisplatin resistance in ovarian cancer via the regulation of the Hippo-YAP pathway.
Xiao L; Shi XY; Li ZL; Li M; Zhang MM; Yan SJ; Wei ZL
J Gynecol Oncol; 2021 Sep; 32(5):e77. PubMed ID: 34132072
[TBL] [Abstract][Full Text] [Related]
31. Polypeptide LTX-315 reverses the cisplatin chemoresistance of ovarian cancer cells via regulating Beclin-1/PI3K/mTOR signaling pathway.
Ma J; Liu L; Ling Y; Zheng J
J Biochem Mol Toxicol; 2021 Sep; 35(9):e22853. PubMed ID: 34309113
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells.
Puca R; Nardinocchi L; Pistritto G; D'Orazi G
Gynecol Oncol; 2008 Jun; 109(3):403-10. PubMed ID: 18395248
[TBL] [Abstract][Full Text] [Related]
33. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells.
Sasaki H; Sheng Y; Kotsuji F; Tsang BK
Cancer Res; 2000 Oct; 60(20):5659-66. PubMed ID: 11059757
[TBL] [Abstract][Full Text] [Related]
34. Circ_0067934 reduces JNK phosphorylation through a microRNA-545-3p/PPA1 axis to enhance tumorigenesis and cisplatin resistance in ovarian cancer.
Yin Y; Li J; Rong J; Zhang B; Wang X; Han H
Immunopharmacol Immunotoxicol; 2022 Apr; 44(2):261-274. PubMed ID: 35179434
[TBL] [Abstract][Full Text] [Related]
35. Tumor-associated macrophages promote cisplatin resistance in ovarian cancer cells by enhancing WTAP-mediated N6-methyladenosine RNA methylation via the CXCL16/CXCR6 axis.
Hong L; Wang X; Zheng L; Wang S; Zhu G
Cancer Chemother Pharmacol; 2023 Jul; 92(1):71-81. PubMed ID: 37272931
[TBL] [Abstract][Full Text] [Related]
36. The p53 upregulated modulator of apoptosis (PUMA) chemosensitizes intrinsically resistant ovarian cancer cells to cisplatin by lowering the threshold set by Bcl-x(L) and Mcl-1.
Yuan Z; Cao K; Lin C; Li L; Liu HY; Zhao XY; Liu L; Deng HX; Li J; Nie CL; Wei YQ
Mol Med; 2011; 17(11-12):1262-74. PubMed ID: 21863213
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA let‑7d‑5p rescues ovarian cancer cell apoptosis and restores chemosensitivity by regulating the p53 signaling pathway via HMGA1.
Chen YN; Ren CC; Yang L; Nai MM; Xu YM; Zhang F; Liu Y
Int J Oncol; 2019 May; 54(5):1771-1784. PubMed ID: 30816441
[TBL] [Abstract][Full Text] [Related]
38. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function.
Fraser M; Bai T; Tsang BK
Int J Cancer; 2008 Feb; 122(3):534-46. PubMed ID: 17918180
[TBL] [Abstract][Full Text] [Related]
39. VPS33B interacts with NESG1 to suppress cell growth and cisplatin chemoresistance in ovarian cancer.
Ning Y; Zeng Z; Deng Y; Feng W; Huang L; Liu H; Lin J; Zhang C; Fan Y; Liu L
Cancer Sci; 2021 May; 112(5):1785-1797. PubMed ID: 33788346
[TBL] [Abstract][Full Text] [Related]
40. Activation of PI3K/AKT/mTOR signaling axis by UBE2S inhibits autophagy leading to cisplatin resistance in ovarian cancer.
Zhang M; Wang J; Guo Y; Yue H; Zhang L
J Ovarian Res; 2023 Dec; 16(1):240. PubMed ID: 38115063
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]